Episode Details
Join us on the latest episode! Our Guest: Anish Shindore, Founder & Managing Partner of GSD Health
What you’ll get out of this episode:
- The importance of merging science and tech in healthcare
- The need for DTX to deliver real patient outcomes
- Overcoming barriers to DTX adoption through education
- The stark differences in U.S. and European startup funding
- How investors are shifting focus towards genuine DTX solutions
- Anish’s vision for DTX as a primary treatment option
Watch
Listen
Read
The Evolution of Digital Therapeutics: Insights and Projections from Anish Shindore
Digital Therapeutics (DTX) is a burgeoning field at the forefront of healthcare innovation. Anish Shindore, with his rich background in biopharma and his role at GSD Health, offers a deep dive into the transformative potential of DTX and the strategic approach necessary for its advancement.
Bridging Science, Technology, and Healthcare
Anish’s career trajectory showcases his commitment to merging science and technology within healthcare. His insights are particularly relevant in the post-COVID era, which has accelerated interest and development in digital therapeutics.
The True Essence of DTX
DTX should transcend beyond just a buzzword to focus on tangible patient outcomes. Anish advocates for a future where DTX seamlessly integrates with healthcare, delivering on the promise of enhanced patient care.
Educating the Stakeholders
A major hurdle for DTX adoption is the lack of effective communication and education among healthcare professionals. Anish parallels this with the pharmaceutical sector’s approach, emphasizing the need for strategic education initiatives to facilitate DTX integration.
Transatlantic Differences and Investor Savvy
Anish critiques the recent trend of European startups eyeing the U.S. market without proper understanding, pointing to the larger seed rounds required in the U.S. due to higher market entry costs. He notes a positive trend of investors becoming more judicious, seeking out genuine digital therapeutic innovations over mere industry jargon.
The Future of DTX in Mainstream Medicine
Anish aspires to see a world where digital therapeutics are a frontline treatment option. He envisions a scenario where a healthcare provider’s first recommendation could be a digital solution rather than traditional medication, signifying trust and efficacy in DTX.
To learn more about Anish Shindore and GSD Health please use the links below:
– Personal LinkedIn – Company LinkedIn – Company Website
Also, be sure to follow DTx Equals on our social channels:
